IP Library › Granted Patent US 9,109,027
Granted Patent B2
US 9,109,027 · App. 13/548,244 · Granted Aug 18, 2015

Antibodies against human angiopoietin 2

Inventors: Ulrich Brinkmann (Weilheim, DE); Remko Albert Griep (Slemmestad, NO); Klaus Kaluza (Bad Heilbrunn, DE); Anita Kavlie (Oslo, NO); Christian Klein (Iffeldorf, DE); Joerg Thomas Regula (Munich, DE); Werner Scheuer (Penzberg, DE)
Assignee: Hoffman-La Roche Inc.
C07K16/22A61K39/00C12N15/85A61K2039/505C07K2317/56C07K2317/565C07K2317/73C07K2317/76C07K2317/92
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,109,027
App. No.
13/548,244
Granted
Aug 18, 2015
Kind
B2
Abstract

The present invention relates to a method of treating a disease or disorder in a patient comprising administering, to a patient in need of such treatment, an antibody which binds specifically to human angiopoietin-2 (ANG-2). The present invention also relates to a method for preventing metastasis in a patient suffering from primary cancer comprising administering, to a patient in need of such preventative treatment, an antibody which binds specifically to human angiopoietin-2 (ANG-2).

Claims (4)

1. A method of treating a retinopathy in a patient comprising administering, to the patient an antibody which binds specifically to human angiopoietin-2 (ANG-2), wherein said antibody comprises:

(A) a heavy chain variable domain which comprises a CDR3 region of SEQ ID NO: 33, a CDR2 region of SEQ ID NO: 34 and a CDR1 region of SEQ ID NO: 35; and

(B) a light chain variable domain which comprises a CDR3 region of SEQ ID NO: 36, a CDR2 region of SEQ ID NO: 37 and a CDR1 region of SEQ ID NO: 38.

2. A method of treating a retinopathy in a patient comprising administering to the patient an antibody which binds specifically to human ANG-2, wherein said antibody comprises a heavy chain variable domain which comprises SEQ ID NO: 39 and a light chain variable domain which comprises SEQ ID NO: 40.

Priority Claims (1)
EP 08021835 · Dec 16, 2008 · regional
Continuity (3)
Division 13358831 · Jan 26, 2012
Continuation 12635825 · Dec 11, 2009
Related Publication 20140065151A1 · Mar 6, 2014